225 related articles for article (PubMed ID: 33311990)
41. LMO7-ALK Fusion in a Lung Adenocarcinoma Patient With Crizotinib: A Case Report.
Yang Y; Zheng H; Li Z; Shi S; Zhong L; Gong L; Lan B
Front Oncol; 2022; 12():841493. PubMed ID: 35664754
[TBL] [Abstract][Full Text] [Related]
42. Excellent response of lung adenocarcinoma harboring a rare SLC8A1 downstream intergenic region ALK fusion to ceritinib treatment: A case report.
Fang L; Ding G; Wang M; Ye Y; Yan X; Ding P; Wang J; Zhang Y
Medicine (Baltimore); 2022 Aug; 101(34):e30255. PubMed ID: 36042596
[TBL] [Abstract][Full Text] [Related]
43. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract][Full Text] [Related]
44. Anaplastic Lymphoma Kinase (ALK) Mutation-Targeting Treatment With Alectinib in Lung Adenocarcinoma and Primary Cutaneous Marginal Zone B-Cell Lymphoma.
Ashish S; Rodriguez RR; Sethi P; Yu F; Raj M
Cureus; 2022 Oct; 14(10):e29922. PubMed ID: 36348885
[TBL] [Abstract][Full Text] [Related]
45. A Novel Intergenic Gene Between
Du J; Wang B; Li M; Wang C; Ma T; Shan J
Front Oncol; 2022; 12():898954. PubMed ID: 35847849
[TBL] [Abstract][Full Text] [Related]
46. Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report.
Zhou H; Xu B; Xu J; Zhu G; Guo Y
Front Oncol; 2021; 11():670907. PubMed ID: 34168990
[TBL] [Abstract][Full Text] [Related]
47. Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer.
Xiang Y; Zhang S; Fang X; Jiang Y; Fang T; Liu J; Lu K
Curr Oncol; 2022 Oct; 29(10):7816-7831. PubMed ID: 36290895
[TBL] [Abstract][Full Text] [Related]
48. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
49. ALK-Rearranged NSCLC With Concomitant HER2-Mutant Breast Cancer Patient Treated With Alectinib, Trastuzumab, and Pertuzumab: A Case Report.
Takayasu H; Kata Y; Otsu Y; Inoue S; Kaneko T
Cureus; 2023 Mar; 15(3):e36711. PubMed ID: 37113357
[TBL] [Abstract][Full Text] [Related]
50. Anaplastic Lymphoma Kinase Mutation (
Carneiro BA; Pamarthy S; Shah AN; Sagar V; Unno K; Han H; Yang XJ; Costa RB; Nagy RJ; Lanman RB; Kuzel TM; Ross JS; Gay L; Elvin JA; Ali SM; Cristofanilli M; Chae YK; Giles FJ; Abdulkadir SA
Clin Cancer Res; 2018 Jun; 24(12):2732-2739. PubMed ID: 29559559
[No Abstract] [Full Text] [Related]
51. Case report: Dramatic response to alectinib in a lung adenosquamous carcinoma patient harbouring a novel CPE-ALK fusion.
Qin Y; Li F; Tan Y; Duan Q; Zhang Q
Front Oncol; 2022; 12():998545. PubMed ID: 37082099
[TBL] [Abstract][Full Text] [Related]
52. Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase (
Li J; Huang K; Ji H; Qian J; Lu H; Zhang Y; Russo A; Romero A; Urbanska EM; Tabbò F; Zhao X; Chu T
Transl Lung Cancer Res; 2023 Dec; 12(12):2505-2519. PubMed ID: 38205204
[TBL] [Abstract][Full Text] [Related]
53. Alectinib relieves ischemic strokes caused by left atrial metastasis in a NSCLC patient with a novel SLC34A2-ALK (exon 1: exon 15) fusion.
Zhou N; Wu M; Yuan M; Wu H; Yu S; Gao X; Wang Y
Lung Cancer; 2023 Sep; 183():107289. PubMed ID: 37542770
[TBL] [Abstract][Full Text] [Related]
54. Superior clinical outcomes in patients with non-small cell lung cancer harboring multiple
Wei Q; Zhang Y; Wang Y; Desai A; Tan S; Huang Q; Pu X; Tian P; Li Y
Transl Lung Cancer Res; 2023 Sep; 12(9):1935-1948. PubMed ID: 37854161
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib: ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2).
Ou SI; Nishio M; Ahn MJ; Mok T; Barlesi F; Zhou C; Felip E; de Marinis F; Kim SW; Pérol M; Liu G; Migliorino MR; Kim DW; Novello S; Bearz A; Garrido P; Mazieres J; Morabito A; Lin HM; Yang H; Niu H; Zhang P; Kim ES
J Thorac Oncol; 2022 Dec; 17(12):1404-1414. PubMed ID: 36096442
[TBL] [Abstract][Full Text] [Related]
56. SDK1-ALK Fusion in a Lung Adenocarcinoma Patient With Excellent Response to ALK Inhibitor Treatment: A Case Report.
Ma L; Xiao J; Guan Y; Wu D; Gu T; Wang J
Front Oncol; 2022; 12():860060. PubMed ID: 35311071
[TBL] [Abstract][Full Text] [Related]
57. Transformation of
Xia G; Huang J; Ni J; Song M; Zhang J; Hofman P; Christopoulos P; Grenda A; Huang M
Transl Lung Cancer Res; 2023 Mar; 12(3):637-646. PubMed ID: 37057117
[TBL] [Abstract][Full Text] [Related]
58. Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.
Yakirevich E; Resnick MB; Mangray S; Wheeler M; Jackson CL; Lombardo KA; Lee J; Kim KM; Gill AJ; Wang K; Gowen K; Sun J; Miller VA; Stephens PJ; Ali SM; Ross JS; Safran H
Clin Cancer Res; 2016 Aug; 22(15):3831-40. PubMed ID: 26933125
[TBL] [Abstract][Full Text] [Related]
59. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
[TBL] [Abstract][Full Text] [Related]
60. Alectinib as first-line treatment for advanced ALK-positive non-small cell lung cancer in the real-world setting: preliminary analysis in a Chinese cohort.
Zou Z; Gu Y; Liang L; Hao X; Fan C; Xin T; Zhao S; Liu Z; Guo Y; Ma K; Li H; Zhang C; Shan L; Zhang Y; Dong G; Peng Y; Shen F; Song X; Christopoulos P; van der Wekken AJ; Okuda K; Ekman S; Xing P; Li J
Transl Lung Cancer Res; 2022 Dec; 11(12):2495-2506. PubMed ID: 36636411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
